Science & Technology
In vivo efficacy and in vitro toxicity assessment of peptide-based therapy HV-3 for the Treatment of Huntington's disease
Department of Health and Human Services — National Institutes of Health
Opportunity #: 1R43NS145846-01
Award Ceiling
$491K
Award Floor
$491K
Close Date
Feb 28, 2027
350 days leftTotal Funding
$491K
Expected Awards
1
Posted Date
Sep 15, 2025
Cost Sharing Required
No
Grants.gov ID
sbir-1R43NS145846-01
Description
SBIR Phase Phase I award: "In vivo efficacy and in vitro toxicity assessment of peptide-based therapy HV-3 for the Treatment of Huntington's disease" awarded to JANUSQ LLC in ROCKY RIVER, Ohio. Funded by Department of Health and Human Services (National Institutes of Health). Award amount: $490,501. The SBIR/STTR programs fund innovative research and development by small businesses, with Phase I for feasibility studies and Phase II for full R&D.
Eligible Applicants
Small businesses
Apply on Grants.gov
Always verify details and apply through the official Grants.gov portal. Information here may not reflect the latest changes.
View on Grants.govDisclaimer: This information is sourced from Grants.gov and may not reflect the most current details. Always verify eligibility requirements, deadlines, and application procedures on the official program website before applying.